February 2026

Egaten

triclabendazole

Novartis Pharmaceuticals Corp

Tablet (oral) · NDA 208711

Last listed protection ended
February 13, 2026

The FDA listed 1 exclusivity for Egaten, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Ended
    Orphan drug exclusivity
    FDA code ODE-228